SPTAN1

SPTAN1 (αII-spectrin/α-fodrin) is a sub-membraneous cytoskeletal scaffolding protein that forms obligate αII/βII spectrin heterodimers through a C-terminal nucleation domain in its last spectrin repeats, organizing the cortical actomyosin network that maintains cell shape, tissue integrity, and membrane protein anchoring (PMID:25631096). In-frame mutations within this heterodimerization domain act dominant-negatively, disrupting heterodimer assembly and driving αII/βII spectrin into insoluble aggregates, the molecular lesion underlying SPTAN1-related epileptic encephalopathy (PMID:29050398, PMID:25631096, PMID:22258530). Through this cortical scaffolding role, SPTAN1 anchors voltage-gated sodium channels at axons (PMID:39988451), supports focal adhesion and integrin signaling required for cochlear hair cell stereocilia and cuticular plate formation (PMID:34708331), and retains active EGFR and TRPV3 at the keratinocyte membrane to drive epidermal terminal differentiation and barrier formation. Beyond structural scaffolding, SPTAN1 functions as a cell density sensor upstream of Hippo signaling: at high density it is phosphorylated and recruits NUMB1/2 to the plasma membrane, sequestering MARK kinases to relieve their inhibition of MST1/2 and thereby suppressing YAP-driven proliferation (PMID:37843276). SPTAN1 additionally participates in DNA inter-strand crosslink repair as a component of an αII-spectrin/FANCA/XPF complex (PMID:28938540), physically interacts with MLH1 to regulate cell migration (PMID:24456667), and supports cancer cell viability, motility, and cell-cell contact (PMID:30856214). Loss-of-function variants causing nonsense-mediated decay produce a distal myopathy (PMID:40023774), and reduced SPTAN1 drives RAC1/c-FOS activation and cystic pathology in ARPKD kidney models (PMID:41742835). In hepatocellular carcinoma, AARS1-mediated lactylation at K1952/K1957 (reversed by HDAC1) disrupts cytoplasmic SPTAN1 phase separation, promoting nuclear translocation and CBFB-dependent NOTCH1/HES1 activation (PMID:41243220).

1. 2012 Medium

   Established that distinct de novo in-frame mutations in the SPTAN1 C-terminal domain produce different spectrin aggregation phenotypes, linking specific lesions to molecular pathology.

   Evidence Transfection of mutant SPTAN1 into neuronal cell lines with immunocytochemistry of aggregation patterns

   PMID:22258530

   Open questions at the time

   • Did not establish how aggregation translates to neuronal dysfunction
   • No quantification of heterodimer disruption per mutation
2. 2014 Medium

   Identified a physical SPTAN1-MLH1 interaction and a SPTAN1-dependent migration function, extending SPTAN1 beyond a purely structural role into mismatch-repair-linked motility control.

   Evidence siRNA knockdown, overexpression, and motility assays across multiple cancer cell lines

   PMID:24456667

   Open questions at the time

   • Interaction not mapped to specific domains
   • Mechanism linking MLH1 status to migration unresolved
3. 2015 Medium

   Synthesized patient and cell data to define the C-terminal nucleation site as the heterodimerization hotspot whose mutation exerts dominant-negative effects in epileptic encephalopathy.

   Evidence Review and synthesis of patient genetics with cell-based aggregation inference

   PMID:25631096

   Open questions at the time

   • Primarily synthesis rather than new experiment
   • Genotype-phenotype mapping incomplete
4. 2016 Medium

   Placed SPTAN1 within an αII-spectrin/FANCA/XPF DNA repair complex and showed miR-128-3p suppression of SPTAN1 attenuates inter-strand crosslink repair, defining a genome-maintenance role.

   Evidence Co-IP, luciferase miRNA target assay, Western blot, cell cycle and chromosomal aberration assays in lung cancer cells

   PMID:28938540

   Open questions at the time

   • Direct structural role of SPTAN1 in repair not defined
   • Single lung cancer context
5. 2017 Medium

   Localized the pathogenic aggregation defect to the Asp2303-Met2309 stretch of the α20 repeat, demonstrating that only heterodimerization-domain mutations drive insoluble αII spectrin accumulation.

   Evidence Triton-X biochemical fractionation, immunocytochemistry on patient fibroblasts, and molecular modelling

   PMID:29050398

   Open questions at the time

   • Did not establish how insoluble aggregates impair neuronal function
   • Single lab
6. 2019 Medium

   Demonstrated that SPTAN1 supports colon cancer cell viability, motility, and cell-cell contact formation, generalizing its role in cell adhesion and growth.

   Evidence siRNA knockdown with viability, migration, and microscopy readouts in CRC lines

   PMID:30856214

   Open questions at the time

   • Molecular effectors downstream not identified
   • Phenotypes correlative
7. 2021 High

   Showed via hair cell conditional knockout that SPTAN1 is required for stereocilia/cuticular plate formation and hearing through focal adhesion and integrin signaling, defining a tissue-specific cytoskeletal role.

   Evidence Hair cell-specific Sptan1 conditional KO mouse, ABR testing, EM/fluorescence morphology, integrin signaling analysis in HEI-OC1 cells

   PMID:34708331

   Open questions at the time

   • Direct integrin-spectrin biochemical linkage not resolved
   • Relevance to human deafness inferred
8. 2023 High

   Defined SPTAN1 as a phosphorylation-dependent cell density sensor that recruits NUMB1/2 to sequester MARK kinases and activate Hippo/MST1/2 signaling, suppressing YAP proliferation.

   Evidence Co-IP, phosphorylation and kinase activity assays, NUMB isoform manipulation, and NUMB/WW45 double-KO mouse liver model

   PMID:37843276

   Open questions at the time

   • Kinase responsible for SPTAN1 phosphorylation not identified
   • Density-sensing trigger mechanism unresolved
9. 2024 Medium

   Established that αII-spectrin organizes the keratinocyte actomyosin cortex under E-cadherin guidance to dissipate tension and retain active EGFR/TRPV3 at the membrane for terminal differentiation.

   Evidence Conditional epidermal Sptan1 KO, laser ablation cortical tension measurement, and EGFR/TRPV3 membrane imaging (preprint)

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Direct EGFR/TRPV3-spectrin binding not shown
10. 2025 Medium

    Expanded SPTAN1 mechanism in three directions: axonal sodium channel anchoring, loss-of-function distal myopathy via NMD, and oncogenic lactylation-driven nuclear signaling in HCC.

    Evidence Zebrafish complementation for NaV localization; patient muscle qPCR/Western with NMD confirmation; mass spectrometry, co-IP, LLPS imaging and tumor models for lactylation

    PMID:39988451 PMID:40023774 PMID:41243220

    Open questions at the time

    • Lactylation functional model from single lab
    • How myopathy phenotype arises from spectrin loss not mechanistically resolved
    • NaV anchoring partners not mapped
11. 2026 Medium

    Linked reduced SPTAN1 to RAC1/c-FOS activation and altered calcium signaling in cystic kidney disease, with CRISPRa restoration rescuing cystic phenotypes.

    Evidence Kidney organoid-on-chip, transgenic mice, CRISPRa rescue, single-cell RNA-seq and live calcium imaging

    PMID:41742835

    Open questions at the time

    • Mechanism connecting spectrin loss to RAC1 activation unresolved
    • Single lab

• The kinase that phosphorylates SPTAN1 during density sensing, and how its diverse scaffolding, repair, and lactylation functions are coordinated within one protein, remain unresolved.
• No identified SPTAN1 density-sensing kinase
• No unified structural model linking heterodimerization, phase separation, and nuclear function